Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,411 across all filing types
Latest filing 2021-07-21 Director's Dealing
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
DIRECTOR/PDMR SHAREHOLDING
Director's Dealing Classification · 100% confidence The document is a Form 6-K filing by AstraZeneca PLC, submitted to the SEC as a report of a foreign issuer. The content focuses on a transaction involving a director (Marc Dunoyer, CFO) receiving shares as part of the acquisition of Alexion Pharmaceuticals. It details the nature of the transaction, share quantities, valuation, and compliance with EU and UK Market Abuse Regulations. This is a notification of a director's dealing (personal share transaction) rather than a full financial report, earnings release, or other types of filings. The document length is about 5108 characters, which is sufficient to contain detailed transaction information. Therefore, the filing type corresponds to Director's Dealing (DIRS).
2021-07-21 English
TOTAL VOTING RIGHTS
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 6-K filed by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. The content specifically relates to 'Total Voting Rights' as of 21 July 2021, providing the number of issued shares and voting rights. It references the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1, indicating it is a regulatory disclosure about voting rights rather than a full report or financial statement. The document length is 3165 characters, which is relatively short and focused on voting rights information. This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements (DVA)', which covers official results from shareholder votes or voting rights announcements. Therefore, the correct classification is DVA with high confidence.
2021-07-21 English
Director/PDMR Shareholding
Director's Dealing Classification · 98% confidence The document is an official notification disseminated via RNS (Regulatory News Service) regarding a 'Transaction by Person Discharging Managerial Responsibilities' (PDMR). Specifically, it details the receipt of Ordinary Shares by the Chief Financial Officer, Marc Dunoyer, as part consideration for the acquisition of Alexion Pharmaceuticals. This type of insider transaction disclosure, mandated by market abuse regulations (EU and UK MAR), is a specific regulatory filing. While it relates to insider dealings (which could sometimes fall under DIRS), the structure, the explicit mention of RNS, and the nature of the disclosure strongly align with a general regulatory announcement that doesn't fit the more specific categories like 10-K, ER, or DIV. Given the options, 'Director's Dealing' (DIRS) is the most specific fit for a PDMR transaction report, although 'Regulatory Filings' (RNS) is also plausible if DIRS is interpreted narrowly. However, since the content is explicitly about director/executive share transactions, DIRS is the superior classification over the general RNS fallback.
2021-07-21 English
Total Voting Rights
Regulatory Filings Classification · 98% confidence The document is a formal notification released via RNS (Regulatory News Service) on July 21, 2021. It explicitly states it is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1 and concerns 'Voting rights and capital'. It provides the total number of voting rights (1,549,116,129) which serves as the denominator for shareholder notification calculations. This content directly relates to regulatory disclosure regarding the company's capital structure and voting rights, fitting the definition of a general regulatory announcement distributed via RNS, rather than a specific report like an Annual Report (10-K) or an Earnings Release (ER). Since it is a standard regulatory disclosure distributed through the RNS system, the most appropriate classification is RNS, which serves as the general regulatory filing category.
2021-07-21 English
ACQUISITION OF ALEXION COMPLETED
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by AstraZeneca PLC, reporting the completion of the acquisition of Alexion Pharmaceuticals. It includes detailed information about the acquisition, financial considerations, share issuance, listing approvals, and forward-looking statements. The document is not a full annual or quarterly report, nor is it a simple announcement of a report publication. It is a regulatory filing reporting a significant corporate event (acquisition completion) with financial and operational details. The Form 6-K is used by foreign issuers to report material events. This fits best under the category of Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit into more specific categories like M&A Activity (TAR) or Merger & Acquisition (MA) filings, which are typically more formal merger proxy statements or tender offer documents. The document is over 11,000 characters, indicating substantive content, but it is primarily an announcement/report of acquisition completion rather than detailed merger proxy or tender offer filings. Therefore, the best classification is Regulatory Filings (RNS).
2021-07-21 English
Acquisition of Alexion completed
Delisting Announcement Classification · 99% confidence The document is a formal announcement released via RNS (Regulatory News Service) on July 21, 2021, titled "Acquisition of Alexion completed." It details the closing of a major corporate transaction (acquisition), including financial considerations, the resulting share capital changes, and the expected commencement of trading for new shares. This type of announcement, which reports a significant corporate event (M&A completion) and includes details about share issuance and listing changes, is typically classified as a major corporate action announcement. While it relates to M&A (TAR), the primary function here is a regulatory disclosure of a completed transaction and its immediate capital structure impact, often disseminated through RNS. Since the document is a full announcement detailing the transaction completion and subsequent share listing details, and it is explicitly distributed via RNS, it fits best under the general regulatory filing category (RNS) or potentially a specific M&A/Capital change category. Given the content focuses heavily on the completion of the acquisition and the subsequent admission of new shares to listing, it is a significant regulatory disclosure. Since there isn't a specific code for 'Acquisition Completion Announcement,' and it is clearly a regulatory news service release, RNS is appropriate. However, the core event is a takeover/merger activity (TAR). Because the document is a comprehensive report on the completion of the acquisition, it is more specific than a general RNS filing. I will classify it as M&A Activity (TAR) as the central theme is the completion of the acquisition of Alexion, which supersedes the general RNS code.
2021-07-21 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.